Article Details
Retrieved on: 2021-07-16 17:48:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Alexion Pharmaceuticals, Inc. ALXN announced that the late-stage study evaluating its long-acting C5 complement inhibitor, Ultomiris, in adults with ...
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here